Alvotech completes private placement with 40 institutional investors

Alvotech (ALVO), a $3.15 billion biotech firm, completed a private placement of 7.5 million treasury shares to approximately 40 institutional investors, primarily from Sweden, Norway, and the UK. Over 80% of the allocated shares went to investors who were not previously Alvotech shareholders, further diversifying the shareholder base. This follows Alvotech's recent strong Q1 earnings, with revenue up 786% year-over-year to $109.9 million, and a collaboration with Dr. Reddy’s Laboratories to co-develop a biosimilar candidate to Keytruda®.

Analysis

Alvotech (NASDAQ: ALVO), a biotech firm valued at $3.15 billion, has successfully executed a private placement of 7.5 million treasury shares, primarily attracting institutional investors from Sweden, Norway, and the UK, with over 80% being new shareholders. This strategic move aims to diversify its shareholder base and enhance the free float of its Swedish Depositary Receipts (SDRs) on Nasdaq Stockholm, where approximately 8.5 million SDRs already trade. Financially, Alvotech exhibits robust performance, evidenced by a remarkable 414% revenue increase over the last twelve months and a healthy gross profit margin of 61%. The company's recent first-quarter results further underscore this momentum, with revenue surging 786% year-over-year to $109.9 million and adjusted earnings per share of $0.35 significantly outperforming the $0.03 consensus estimate, driven by strong product launches including SELARSDI in the U.S. and sales of biosimilars AVT02 and AVT04. Consequently, Alvotech has raised its full-year 2025 revenue guidance to $600-$700 million and adjusted EBITDA to $200-$280 million. The company's pipeline includes two approved biosimilars (alternatives to Humira and Stelara) and nine additional candidates, supported by global commercial partnerships with entities like Teva Pharmaceuticals and STADA Arzneimittel AG. A recent collaboration with Dr. Reddy’s Laboratories to co-develop a biosimilar for Keytruda® signals expansion into the oncology sector. However, UBS analysts caution about challenges in the US generic drug market, citing limited cost pass-through capabilities and the perceived insufficient impact of recent executive orders promoting biosimilars, a context relevant to Alvotech's U.S. operations.

Key Decisions for Investors

• Investors should consider Alvotech's strong revenue growth, significantly improved earnings, and successful private placement as positive catalysts, indicative of robust operational execution and investor confidence.
• The expansion of Alvotech's biosimilar pipeline, particularly the collaboration with Dr. Reddy's for a Keytruda® biosimilar, presents a significant long-term growth opportunity that warrants monitoring for development milestones and market penetration.
• Despite the company's positive trajectory and increased 2025 guidance, investors should remain cognizant of the broader US generic market challenges, including pricing pressures and policy uncertainties highlighted by UBS, which could impact future profitability.
• The diversification of the shareholder base and increased SDR free float on Nasdaq Stockholm may improve liquidity and visibility, potentially attracting a wider range of institutional investors.